Integral Health Asset Management’s Regenxbio RGNX Stock Holding History

Integral Health Asset Management’s Portfolio RGNX Stock Details RGNX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$9.58M	Sell	800,000 -700,000	-47%	-$5.81M	0.38%	63
2026 Q1	$12.6M	Buy	1,500,000 +300,000	+25%	+$3.15M	0.6%	45
2025 Q4	$17.3M	Buy	1,200,000 +100,000	+9%	+$1.25M	0.86%	41
2025 Q3	$10.6M	Buy	1,100,000 +400,000	+57%	+$3.54M	0.72%	50
2025 Q2	$5.75M	Sell	700,000 -225,000	-24%	-$1.88M	0.53%	48
2025 Q1	$6.61M	Buy	925,000 +25,000	+3%	+$186K	0.7%	43
2024 Q4	$6.96M	Sell	900,000 -375,000	-29%	-$3.52M	0.59%	54
2024 Q3	$13.4M	Buy	1,275,000 +325,000	+34%	+$3.96M	1.5%	19
2024 Q2	$11.1M	Buy	950,000 +190,000	+25%	+$2.96M	1.06%	32
2024 Q1	$16M	Buy	760,000 +435,000	+134%	+$7.74M	1.49%	24
2023 Q4	$5.83M	Buy	+325,000	New	+$5.72M	0.79%	53
2022 Q2	–	Sell	-90,000	Closed	-$2.99M	–	82
2022 Q1	$2.99M	Buy	90,000 +15,000	+20%	+$417K	0.78%	46
2021 Q4	$2.45M	Buy	75,000 +20,000	+36%	+$681K	0.68%	46
2021 Q3	$2.31M	Buy	+55,000	New	+$1.98M	0.66%	52

Other funds holding RGNX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

Integral Health Asset Management's RGNX Position: Q2 2026 in Review

Integral Health Asset Management reduced its Regenxbio (RGNX) stake by 47% in Q2 2026, selling an estimated $5.81M and leaving 800,000 shares worth $9.58M. The position accounts for 0.38% of the portfolio, ranked #63.

Integral Health Asset Management first reported a position in RGNX in Q3 2021 and has held it in 14 quarters since. The position peaked at $17.3M in Q4 2025. 164 funds tracked by Wall St. Rank hold RGNX as of Q2 2026.

Integral Health Asset Management held 800,000 shares of Regenxbio worth $9.58M as of Q2 2026.
Integral Health Asset Management sold 700,000 Regenxbio shares in Q2 2026, an estimated $5.81M.
Regenxbio made up 0.38% of Integral Health Asset Management's portfolio in Q2 2026, its #63 holding.
Integral Health Asset Management first reported a position in Regenxbio in Q3 2021 and has held it in 14 quarters since.
Integral Health Asset Management's Regenxbio position peaked at $17.3M in Q4 2025.
164 funds tracked by Wall St. Rank held Regenxbio as of Q2 2026.

Based on Integral Health Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.